Pharma pumps up lobbying spend

Share this article:

The pharmaceutical industry increased its lobbying presence during the first quarter of this year. Roll Call's Political MoneyLine blog notes that Pfizer, Johnson & Johnson, Bayer and Merck were at the top of the list of pharma companies whose lobbying outlays were up from the fourth quarter of 2013.

Among the increases:

Pfizer upped its lobbying efforts this quarter by almost 53%, to $3.9 million, compared to $2.1 million in the fourth quarter, while Novartis put close to $2.6 million toward lobbying in the first quarter, compared to $920,000 in the fourth quarter of last year.

J&J dialed up its efforts, to $2.1 million, up from $860,000, and Merck more than doubled its efforts, with $2 million this quarter, compared to $820,000 last quarter.

But some drugmakers dialed back their efforts: Bristol-Myers Squibb proffered $520,000 during the first quarter, down from $740,000 last quarter, while Novo Nordisk reduced its outlay to $710,000, compared to $820,000 last quarter.

Share this article:

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Novartis apologizes for slow reporting

Novartis is apologizing to Japan after the Ministry of Health, Labor and Welfare said the company had dragged its feet reporting adverse events for two of its cancer drugs.

J&J pulls morcellator from market

The company is calling the move a withdrawal, as opposed to a recall.

Pfizer buys two Baxter vaccines

The meningitis and encephalitis medications earned a combined $300 million last year.